1. Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.
- Author
-
Brandi, Paola, Conejero, Laura, Cueto, Francisco J., Martínez-Cano, Sarai, Dunphy, Gillian, Gómez, Manuel J., Relaño, Carlos, Saz-Leal, Paula, Enamorado, Michel, Quintas, Ana, Dopazo, Ana, Amores-Iniesta, Joaquín, del Fresno, Carlos, Nistal-Villán, Estanislao, Ardavín, Carlos, Nieto, Antonio, Casanovas, Miguel, Subiza, José Luis, and Sancho, David
- Abstract
MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. However, its mechanism of action remains poorly understood. Here, we find that intranasal prophylaxis with MV130 modulates the lung immune landscape and provides long-term heterologous protection against viral respiratory infections in mice. Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1 -deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. Moreover, pharmacological inhibition of trained immunity with metformin abrogates the protection conferred by MV130 against influenza A virus respiratory infection. MV130 induces reprogramming of both mouse bone marrow progenitor cells and in vitro human monocytes, promoting an enhanced cytokine production that relies on a metabolic shift. Our results unveil that the mucosal administration of a fully inactivated bacterial vaccine provides protection against viral infections by a mechanism associated with the induction of trained immunity. [Display omitted] • MV130 reduces morbi-mortality in mouse models of viral respiratory infection • MV130 modulates mouse immunity complying with key features of trained immunity • MV130 promotes reprogramming of mouse bone marrow progenitors • MV130 induces trained immunity in human monocytes Brandi et al. investigate the mechanism of action of an inactivated polybacterial mucosal immunomodulator, MV130, which confers protection in patients suffering from recurrent respiratory infections. They show that MV130 induces trained immunity both in mouse bone marrow progenitors, resulting in protection from viral infection, and in human monocytes in vitro. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF